Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRILOGY: Long-term Extension Study of Guselkumab in Pediatric Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
NCT06663332Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, open-label trial of guselkumab in Crohn's disease, ulcerative colitis (UC) and juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2024; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT06663332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663332.